Tuesday, June 28, 2011 (Last Updated: 06/30/2011)
TUESDAY, June 28 (HealthDay News) -- Low-dose vitamin D and calcium supplementation do not reduce the overall incidence of nonmelanoma skin cancer (NMSC) in postmenopausal women, but may benefit women with a history of NMSC, according to a study published online June 27 in the Journal of Clinical Oncology.
Jean Y. Tang, M.D., Ph.D., from the Stanford School of Medicine in Redwood City, Calif., and colleagues analyzed the effect of vitamin D intake along with calcium supplementation on skin cancer, using data from 36,282 postmenopausal women, aged 50 to 79 years. The women were enrolled in the Women's Health Initiative calcium and vitamin D clinical trial and were randomized to receive 1,000 mg of elemental calcium and 400 IU of vitamin D3 (CaD) every day or a placebo, and they were followed up for an average of seven years. NMSC and melanoma were self-reported annually and melanoma skin cancers were assessed by a physician.
The investigators found that there was no difference in incident NMSC or melanoma rates between treatment and placebo groups. There was a reduced risk of melanoma in women with history of NMSC assigned to CaD compared to those receiving placebo (hazard ratio, 0.43), which was not seen in women without a history of NMSC.
"Vitamin D supplementation at a relatively low dose plus calcium did not reduce the overall incidence of NMSC or melanoma. However, in women with history of NMSC, CaD supplementation reduced melanoma risk, suggesting a potential role for calcium and vitamin D supplements in this high-risk group," the authors write.
Hematology & Oncology
Copyright © 2011 HealthDay. All rights reserved.